RECCE PHARMACEUTICAL ORDINARY (RCE) Short Interest
RECCE PHARMACEUTICAL ORDINARY (ASX:RCE) had 0.00% of shares reported as short positions as of 16 July 2026, representing 1,195 shares. RECCE PHARMACEUTICAL ORDINARY operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Recce Pharmaceuticals
Recce Pharmaceuticals Ltd is an Australian pharmaceutical company focused on developing a new class of synthetic anti-infectives to combat antibiotic-resistant superbugs. Their lead candidate, RECCE® 327, has received Qualified Infectious Disease Product (QIDP) designation from the FDA, offering potential market exclusivity. The company aims to provide effective treatments against a broad range of bacteria and viral indications.
Short position
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4RCE intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Recce Pharmaceuticals
Latest RCE news
All news- Why Recce Pharmaceuticals (ASX:RCE) Is Expanding Its ASEAN Footprint
kalkine
- Recce strengthens IP for anti-infectives with Vietnamese patent grant
stockhead
- Vietnamese Patent Granted for RECCE Anti-Infectives
asx
- Share Purchase Plan - Letter and Offer Booklet
asx
- Application for quotation of securities - RCE
asx
About
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss RCE
Start a research thread or post the first pulse update